心臓　55/7　2023年7月号

出版社： 日本医学出版
発行日： 2023-07-15
分野： 臨床医学：内科  >  雑誌
ISSN： 05864488
雑誌名：
電子書籍版： 2023-07-15
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

2,200 円(税込)

購入する

目次

  • Open HEART
    　基礎研究のすすめ

    HEART’s Selection
    　成人先天性心疾患の未来
    　1．本邦の成人先天性心疾患診療の現状
    　2．成人先天性心疾患のシャント性肺動脈性肺高血圧に対するTreat and Repair
    　3．成人先天性心疾患に対する心房中隔穿刺
    　4．成人先天性心疾患の突然死予防
    　5．成人先天性心疾患に対するカテーテルインターベンションの展望
    　6．成人先天性心疾患における外科治療

    [連載]HEART's　Column
    Authorが語る日本発のクリニカル・エビデンス：論文の解説と発表後の展望
    Predictors of long-term mortality among perioperative survivors of Fontan operation

    [連載]HEART’s Up To Date
    循環器医が知っておくべき最新のエビデンス

    HEART’s Original
    [症例]
    原発性肺癌心筋転移に免疫チェックポイント阻害薬関連心筋炎を生じた１例
    [Editorial Comment]
    森論文に対するEditorial　Comment
    [症例]
    3回目のmRNA COVID-19ワクチン接種による急性心筋炎を疑った1例
    [Editorial Comment]
    西尾論文に対するEditorial　Comment
    [症例]
    可動性の強いCalcified amorphous tumorに対し準緊急手術を施行した１例
    [Editorial Comment]
    徳田論文に対するEditorial　Comment
    [Editorial Comment]
    徳田論文に対するEditorial　Comment
    [症例]
    免疫チェックポイント阻害薬関連心毒性発症後の心筋ストレインの経時的変化を観察評価した1例
    [Editorial Comment]
    大窪論文に対するEditorial　Comment

    研究会
    　第29回　肺塞栓症研究会・学術集会

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【HEART' s Selection】

P.636 掲載の参考文献
1) 日本循環器学会 : 成人先天性心疾患診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2017_ichida_h.pdf (cited 2023 May 16)
 
2) Baumgartner H, De Backer J, Babu-Narayan SV, et al ; ESC Scientific Document Group : 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J 2021 ; 42 : 563-645
 
3) Stout KK, Daniels CJ, Aboulhosn JA, et al : 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease : Executive Summary : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019 ; 73 : 1494-1563
 
4) Wu MH, Lu CW, Chen HC, et al : Adult Congenital Heart Disease in a Nationwide Population 2000-2014 : Epidemiological Trends, Arrhythmia, and Standardized Mortality Ratio. J Am Heart Assoc 2018 ; 7 : e007907
 
5) Akagi T : Congenital heart disease in Japan. Eur Heart J Suppl 2012 ; 14 : A47-A48
 
6) Shiina Y, Toyoda T, Kawasoe Y, et al : Prevalence of adult patients with congenital heart disease in Japan. Int J Cardiol 2011 ; 146 : 13-16
 
7) Takaya Y, Akagi T, Sakamoto I, et al : Efficacy of treat-and-repair strategy for atrial septal defect with pulmonary arterial hypertension. Heart 2022 ; 108 : 382-387
 
8) Ohuchi H, Hayama Y, Nakajima K, et al : Incidence, Predictors, and Mortality in Patients With Liver Cancer After Fontan Operation. J Am Heart Assoc 2021 ; 10 : e016617
PubMed
9) Lammers AE, Diller GP, Lober R, et al : Maternal and neonatal complications in women with congenital heart disease : a nationwide analysis. Eur Heart J 2021 ; 42 : 4252-4260
 
10) Lowe BS, Therrien J, Ionescu-Ittu R, et al : Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes. J Am Coll Cardiol 2011 ; 58 : 538-546
 
11) Horiuchi C, Kamiya CA, Ohuchi H, et al : Pregnancy outcomes and mid-term prognosis in women after arterial switch operation for dextro-transposition of the great arteries-Tertiary hospital experiences and review of literature. J Cardiol 2019 ; 73 : 247-254
 
12) Ochiai R, Yao A, Kinugawa K, et al : Status and Future Needs of Regional Adult Congenital Heart Disease Centers in Japan. Circ J 2011 ; 75 : 2220-2227
 
13) Ochiai R, Kato H, Misaki Y, et al : Preferences Regarding Transfer of Patients With Congenital Heart Disease Who Attend Children's Hospital. Circ J 2019 ; 83 : 824-830
 
14) Ochiai R, Kato H, Akiyama N, et al : Nationwide Survey of the Transfer of Adults With Congenital Heart Disease From Pediatric Cardiology Departments to Adult Congenital Heart Disease Centers in Japan. Circ J 2016 ; 80 : 1242-1250
PubMed
15) Mylotte D, Pilote L, Ionescu-Ittu R, et al : Specialized adult congenital heart disease care : the impact of policy on mortality. Circulation 2014 ; 129 : 1804-1812
 
16) Stout KK, Daniels CJ, Aboulhosn JA, et al : 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019 ; 73 : e81-e192
 
17) Brida M, Diller G-P, Gatzoulis MA : Systemic Right Ventricle in Adults With Congenital Heart Disease : Anatomic and Phenotypic Spectrum and Current Approach to Management. Circulation 2018 ; 137 : 508-518
 
18) Gatzoulis MA, Landzberg M, Beghetti M, et al ; MAESTRO Study Investigators : Evaluation of Macitentan in Patients With Eisenmenger Syndrome. Circulation 2019 ; 139 : 51-63
 
P.643 掲載の参考文献
1) Tamura Y, Kumamaru H, Satoh T, et al ; Japan PH Registry (JAPHR) Network : Effectiveness and Outcome of Pulmonary Arterial Hypertension-Specific Therapy in Japanese Patients With Pulmonary Arterial Hypertension. Circ J 2017 ; 82 : 275-282
 
2) Ogawa A, Ejiri K, Matsubara H : Long-term patient survival with idiopathic/heritable pulmonary arterial hypertension treated at a single center in Japan. Life Sci 2014 ; 118 : 414-9
 
3) Fukuda K, Date H, Doi S, et al ; Japanese Circulation Society and the Japanese Pulmonary Circulation and Pulmonary Hypertension Society Joint Working Group. Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017). Circ J 2019 ; 83 : 842-945
 
4) Humbert M, Kovacs G, Hoeper MM, et al ; ESC/ERS Scientific Document Group : 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022 ; 43 : 3618-3731
 
5) Baumgartner H, De Backer J : The ESC Clinical Practice Guidelines for the Management of Adult Congenital Heart Disease 2020. Eur Heart J 2020 ; 41 : 4153-4154
 
6) Barst RJ, Ivy DD, Foreman AJ, et al : Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL Registry). Am J Cardiol 2014 ; 113 : 147-155
 
7) Manes A, Palazzini M, Leci E, et al : Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease : a comparison between clinical subgroups. Eur Heart J 2014 ; 35 : 716-724
 
8) Inaba T, Yao A, Nakao T, et al : Volumetric and functional assessment of ventricles in pulmonary hypertension on 3-dimensional echocardiography. Circ J 2013 ; 77 : 198-206
 
9) 八尾厚史, 相馬桂, 稲葉俊郎 : 心房中隔欠損シャント性肺動脈性肺高血圧に対するTreat and Repairの適用. 日成人先天性心疾患学誌 2019 ; 8 : 12-24
 
10) Yao A : "Treat-and-Repair" Strategy for Atrial Septal Defect and Associated Pulmonary Arterial Hypertension. Circ J 2016 ; 80 : 69-71
 
11) Takaya Y, Akagi T, Sakamoto I, et al : Efficacy of treat-and-repair strategy for atrial septal defect with pulmonary arterial hypertension. Heart 2022 ; 108 : 382-387
 
12) Yao A, Inuzuka R, Mizuno A, et al : JNCVD-ACHD investigators : Status of adult outpatients with congenital heart disease in Japan : The Japanese Network of Cardiovascular Departments for Adult Congenital Heart Disease Registry. J Cardiol 2022 ; 80 : 525-531
 
P.648 掲載の参考文献
1) Aoki H, Nakamura Y, Takeno S, Takemura T : A new procedure for a trans-conduit puncture by grasping the dilator tip with a snare catheter : an alternative access method during catheter ablation of supraventricular tachycardias after an extracardiac Fontan operation. Heart Rhythm 2014 ; 11 : 1492-1494
 
2) Santangeli P, Di Biase L, Burkhardt JD, et al : Transseptal access and atrial fibrillation ablation guided by intracardiac echocardiography in patients with atrial septal closure devices. Heart Rhythm 2011 ; 8 : 1669-1675
 
3) Anderson JH, Adamson T, Migliati E, et al : Perforating the GORER CARDIOFORM septal occluder and atrial septal defect occluder to gain access to the left atrium. Catheter Cardiovasc Interv 2020 ; 96 : E660-E665
 
4) Kumamoto T, Sumitomo N, Kobayashi T, et al : Implantation of ileofemoral stents : A novel approach for bilateral occlusions of the iliofemoral vein in a patient with a Glenn operation. HeartRhythm Case Rep 2015 ; 2 : 138-141
 
P.653 掲載の参考文献
1) Oechslin EN, Harrison DA, Connelly MS, et al : Mode of death in adults with congenital heart disease. Am J Cardiol 2000 ; 86 : 1111-1116
 
2) Koyak Z, Harris L, de Groot JR, et al : Sudden cardiac death in adult congenital heart disease. Circulation 2012 ; 126 : 1944-1954
 
3) Diller GP, Kempny A, Alonso-Gonzalez R, et al : Survival Prospects and Circumstances of Death in Contemporary Adult Congenital Heart Disease Patients Under Follow-Up at a Large Tertiary Centre. Circulation 2015 ; 132 : 2118-2125
 
4) Engelings CC, Helm PC, Abdul-Khaliq H, et al : Cause of death in adults with congenital heart disease-An analysis of the German National Register for Congenital Heart Defects. Int J Cardiol 2016 ; 211 : 31-36
 
5) Pillutla P, Shetty KD, Foster E : Mortality associated with adult congenital heart disease : Trends in the US population from 1979 to 2005. Am Heart J 2009 ; 158 : 874-879
 
6) Silka MJ, Hardy BG, Menashe VD, Morris CD : A population-based prospective evaluation of risk of sudden cardiac death after operation for common congenital heart defects. J Am Coll Cardiol 1998 ; 32 : 245-251
 
7) Moore B, Yu C, Kotchetkova I, et al : Incidence and clinical characteristics of sudden cardiac death in adult congenital heart disease. Int J Cardiol 2018 ; 254 : 101-106
 
8) Miyazaki A, Sakaguchi H, Ohuchi H, et al : The clinical characteristics of sudden cardiac arrest in asymptomatic patients with congenital heart disease. Heart Vessels 2015 ; 30 : 70-80
 
9) Oliver JM, Gallego P, Gonzalez AE, et al : Predicting sudden cardiac death in adults with congenital heart disease. Heart 2021 ; 107 : 67-75
 
10) Vehmeijer JT, Koyak Z, Budts W, et al : Prevention of Sudden Cardiac Death in Adults With Congenital Heart Disease : Do the Guidelines Fall Short? Circ Arrhythm Electrophysiol 2017 ; 10 : e005093
PubMed
11) Miyazaki A : Rhythm Disturbance/Sudden death. In : Masuda M, Niwa K, eds. Adult Congenital Heart Disease. Focusing on Intervention. Singapore : Springer Nature ; 2017. p.73-86
 
12) Vehmeijer JT, Koyak Z, Leerink JM, et al : Identification of patients at risk of sudden cardiac death in congenital heart disease : The PRospEctiVE study on implaNTable cardIOverter defibrillator therapy and suddeN cardiac death in Adults with Congenital Heart Disease (PREVENTION-ACHD). Heart Rhythm 2021 ; 18 : 785-792
 
13) Ohuchi H, Kawata M, Uemura H, et al ; Japanese Circulation Society Joint Working Group : JCS 2022 Guideline on Management and Re-Interventional Therapy in Patients With Congenital Heart Disease Long-Term After Initial Repair. Circ J 2022 ; 86 : 1591-1690
 
14) Possner M, Tseng SY, Alahdab F, et al : Risk Factors for Mortality and Ventricular Tachycardia in Patients With Repaired Tetralogy of Fallot : A Systematic Review and Meta-analysis. Can J Cardiol 2020 ; 36 : 1815-1825
 
15) Waldmann V, Bouzeman A, Duthoit G, et al ; DAI-T4F Investigators : Long-Term Follow-Up of Patients With Tetralogy of Fallot and Implantable Cardioverter Defibrillator : The DAI-T4F Nationwide Registry. Circulation 2020 ; 142 : 1612-1622
 
16) Kapel GFL, Laranjo S, Blom NA, et al : Impact of surgery on presence and dimensions of anatomical isthmuses in tetralogy of Fallot. Heart 2018 ; 104 : 1200-1207
 
17) Kapel GF, Sacher F, Dekkers OM, et al : Arrhythmogenic anatomical isthmuses identified by electroanatomical mapping are the substrate for ventricular tachycardia in repaired Tetralogy of Fallot. Eur Heart J 2017 ; 38 : 268-276
 
18) Cohen MI, Khairy P, Zeppenfeld K, et al : Preventing Arrhythmic Death in Patients With Tetralogy of Fallot : JACC Review Topic of the Week. J Am Coll Cardiol 2021 ; 77 : 761-771
 
19) Harrild DM, Berul CI, Cecchin F, et al : Pulmonary valve replacement in tetralogy of Fallot : impact on survival and ventricular tachycardia. Circulation 2009 ; 119 : 445-451
 
20) Bokma JP, Geva T, Sleeper LA, et al : A propensity score-adjusted analysis of clinical outcomes after pulmonary valve replacement in tetralogy of Fallot. Heart 2018 ; 104 : 738-744
 
21) Caldaroni F, Lo Rito M, Chessa M, et al : Surgical ablation of ventricular tachycardia in patients with repaired tetralogy of Fallot†. Eur J Cardiothorac Surg 2019 ; 55 : 845-850
 
22) Nevvazhay T, Zeppenfeld K, Brouwer C, Hazekamp M : Intraoperative cryoablation in late pulmonary valve replacement for tetralogy of Fallot. Interact Cardiovasc Thorac Surg 2020 ; 30 : 780-782
 
23) Sandhu A, Ruckdeschel E, Sauer WH, et al : Perioperative electrophysiology study in patients with tetralogy of Fallot undergoing pulmonary valve replacement will identify those at high risk of subsequent ventricular tachycardia. Heart Rhythm 2018 ; 15 : 679-685
 
24) Krieger EV, Zeppenfeld K, DeWitt ES, et al : Arrhythmias in Repaired Tetralogy of Fallot : A Scientific Statement From the American Heart Association. Circ Arrhythm Electrophysiol 2022 ; 15 : e000084
PubMed
25) Venkatesh P, Evans AT, Maw AM, et al : Predictors of Late Mortality in D-Transposition of the Great Arteries After Atrial Switch Repair : Systematic Review and Meta-Analysis. J Am Heart Assoc 2019 ; 8 : e012932
 
26) Khairy P : Sudden cardiac death in transposition of the great arteries with a Mustard or Senning baffle : the myocardial ischemia hypothesis. Curr Opin Cardiol 2017 ; 32 : 101-107
 
27) Khairy P, Harris L, Landzberg MJ, et al : Sudden death and defibrillators in transposition of the great arteries with intra-atrial baffles : a multicenter study. Circ Arrhythm Electrophysiol 2008 ; 1 : 250-257
 
28) Kharbanda RK, de Groot NMS : Prediction and prevention of sudden cardiac death in transposition of the great arteries : A step closer. Int J Cardiol 2019 ; 288 : 68-69
 
29) Chaix MA, Chergui M, Leduc C, Khairy P : Sudden death in transposition of the great arteries with atrial switch surgery : Autopsy evidence of acute myocardial ischemia despite normal coronary arteries. Int J Cardiol 2019 ; 288 : 65-67
PubMed
P.660 掲載の参考文献
1) Masura J, Gavora P, Formanek A, Hijazi ZM : Transcatheter closure of secundum atrial septal defects using the new self-centering Amplatzer septal occluder : Initial human experience. Cathet Cardiovasc Diagn 1997 ; 42 : 388-393
 
2) Haas NA, Soetemann DB, Ates I, et al : Closure of Secundum Atrial Septal Defects by Using the Occlutech Occluder Devices in More Than 1300 Patients : The IRFACODE Project : A Retrospective Case Series. Catheter Cardiovasc Interv 2016 ; 88 : 571-581
 
3) Sommer RJ, Love BA, Paolillo JA, et al ; ASSURED Investigators : ASSURED clinical study : New GORE(R) CARDIOFORM ASD occluder for transcatheter closure of atrial septal defect. Catheter Cardiovasc Interv 2020 ; 95 : 1285-1295
 
4) 日本循環器学会/日本心臓病学会/日本心臓血管外科学会/日本血管外科学会/日本胸部外科学会 : 2021年改訂版 先天性心疾患, 心臓大血管の構造的疾患 (structural heart disease) に対するカテーテル治療のガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Sakamoto_Kawamura.pdf (cited 2023 May 01)
 
5) 塚田正範, 北野正尚, 松岡道生, ほか : 経食道心エコーを用いた心房中隔欠損に対する治療適応の評価方法の検討. 日小循誌 2013 ; 29 : s275
 
6) Stout KK, Daniels CJ, Aboulhosn JA, et al : 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease : Executive Summary : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019 ; 73 : 1494-1563
 
7) Baumgartner H, Backer JD, Babu-Narayan SV, et al ; ESC Scientific Document Group : 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J 2021 ; 42 : 612-615
 
8) Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery ; Shimizu H, Okada M, Tangoku A, et al : Thoracic and cardiovascular surgeries in Japan during 2017 Annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 2020 ; 68 : 414-449
 
9) Santhanam H, Yang L, Chen Z, et al : A meta-analysis of transcatheter device closure of perimembranous ventricular septal defect. Int J Cardiol 2018 ; 254 : 75-83
 
10) Tomita H, Kim SH, Inuzuka R, et al : Stent Implantation for Congenital Heart Diseases in Japan-Comprehensive Analysis From the Japanese Society of Congenital Interventional Cardiology Registry. Circ J 2021 ; 85 : 1517-1524
 
P.666 掲載の参考文献
1) Srinathan SK, Bonser RS, Sethia B, et al : Changing practice of cardiac surgery in adult patients with congenital heart disease. Heart 2005 ; 91 : 207-212
 
2) Warnes CA : The adult with congenital heart disease. Born to be bad? J Am Coll Cardiol 2005 ; 46 : 1-8
 
3) Klcovansky J, Sondergaard L, Helvind M, Andersen HO : Cardiac surgery in grown-up congenital heart patients. Will the surgical workload increase? Interact Cardiovasc Thorac Surg 2008 ; 7 : 84-89
 
4) Marelli AJ, Gurvitz M : From numbers to guidelines. Prog Cardiovasc Dis 2011 ; 53 : 239-246
 
5) Horer J, Vogt M, Wottke M, et al : Evaluation of the Aristotle complexity models in adult patients with congenital heart disease. Eur J Cardiothorac Surg 2013 ; 43 : 128-135
 
6) Dearani JA, Connolly HM, Martinez R, et al : Caring for adults with congenital cardiac disease : successes and challenges for 2007 and beyond. Cardiol Young 2007 ; 17 (Suppl 2) : 87-96
 
7) Marelli AJ, Ionescu-Ittu R, Mackie AS, et al : Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. Circulation 2014 ; 130 : 749-756
 
8) Dearani JA, Mavriodis C, Quintessenza J, et al : Surgical advances in the treatment of adults with congenital heart disease. Curr Opin Pediatr 2009 ; 21 : 565-572
 
9) Warnes CA, Liberthson R, Danielson GK, et al : Task force 1 : the changing profile of congenital heart disease in adult life. J Am Coll Cardiol 2001 ; 37 : 1170-1175
 
10) Hoffman JI, Kaplan S, Liberthson RR : Prevalence of congenital heart disease. Am Heart J 2004 ; 147 : 425-439
 
11) Li J, Zhang G, Holtby H, et al : Adverse effects of dopamine on systemic hemodynamic status and oxygen transport in neonates after the Norwood procedure. J Am Coll Cardiol 2006 ; 48 : 1859-1864
 
12) Neiminen HP, Jokinen EV, Sairanen HI : Causes of late deaths after pediatric cardiac surgery : a population-based study. J Am Coll Cardiol 2007 ; 50 : 1263-1271
 
13) 厚生労働省 : 循環器病対策推進基本計画 (令和2年10月). https://www.mhlw.go.jp/content/000688359.pdf (cited 2023 May 16)
 
14) Padalino MA, Speggiorin S, Rizzoli G, et al : Midterm results of surgical intervention for congenital heart disease in adults : An Italian multicenter study. J Thorac Cardiovasc Surg 2007 ; 134 : 106-113
 
15) Vida VL, Berggren H, Brawn WJ, et al : Risk of Surgery for Congenital Heart Disease I the Adult : Multicentered European Study. Ann Thorac Surg 2007 ; 83 : 161-168
 
16) Vouhe PR : Adult Congenital Surgery : Current Management. Semin Thorac Cardiovasc Surg 2011 ; 23 : 209-215
 
17) Kim YY, Gauvreau K, Bacha EA, et al : Risk factors for death after adult congenital heart surgery in pediatric hospitals. Circ Cardiovasc Qual Outcomes 2011 ; 4 : 433-439
 
18) Putman LM, van Gameren M, Meijboom FJ, et al : Seventeen years of adult congenital heart surgery : A single centre experience. Eur J Cardiothorac Surg 2009 ; 36 : 96-104
PubMed
19) Stellin G, Vida VL, Padalino MA, Rizzoli G ; European Congenital Heart Surgeons Association : Surgical outcome for congenital heart malformations in the adult age : A multicentric European study. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2004 ; 7 : 95-101
 
20) Wauthy P, Massaut J, Sanoussi A, et al : Ten-year experience with surgical treatment of adults with congenital cardiac disease. Cardiol Young 2011 ; 21 : 39-45
 
21) Giamberti A, Chessa M, Abella R, et al : Morbidity and mortality risk factors in adults with congenital heart disease undergoing cardiac reoperations. Ann Thorac Surg 2009 ; 88 : 1284-1289
 
22) Vida V L, Zanotto L, Torlai Triglia L, et al ; Surgery for Adult Patients with Congenital Heart Disease : Results from the European Database. J Clin Med 2020 ; 9 : 2493
PubMed
23) Berdat PA, Immer F, Pfammatter JP, Carrel T : Reoperations in adults with congenital heart disease : Analysis of early outcome. Int J Cardiol 2004 ; 93 : 239-245
 
24) Padalino MA, Speggiorin S, Rizzoli G, et al : Midterm results of surgical intervention for congenital heart disease in adults : An Italian multicenter study. J Thorac Cardiovasc Surg 2007 ; 134 : 106-113
 
25) MacDonald ST, Carminati M, Chessa M : Managing adults with congenital heart disease in the catheterization laboratory : State of the art. Expert Rev Cardiovasc Ther 2010 ; 8 : 1741-1752
 
26) Dore A, Glancy DL, Stone S, et al : Cardiac surgery for grown-up congenital heart patients : Survey of 307 consecutive operations from 1991 to 1994. Am J Cardiol 1997 ; 80 : 906-913
 
27) Dearani JA, Danielson GK, Puga FJ, et al : Late Follow-Up of 1095 Patients Undergoing Operation for Complex Congenital Heart Disease Utilizing Pulmonary Ventricule to Pulmonary Artery Conduits. Ann Thorac Surg 2003 ; 75 : 399-410
 
28) Miyazaki T, Yamagishi M, Nakashima A, et al : Expanded polytetrafluoroetylene valved conduit and patch with bulging sinuses in right ventricular outflow tract reconstruction. J Thorac Cardiovasc Surg 2007 ; 134 : 327-332
 
29) Kido T, Steringer MT, Heinisch PP, et al : Surgical reintervention on the neo-aorta after the Norwood operation. Eur J Cardiothorac Surg 2022 ; 62 : ezac117
PubMed

【連載】

P.670 掲載の参考文献
1) Inai K, Inuzuka R, Ono H, Nii M, Ohtsuki S, Kurita Y, Takeda A, Hirono K, Takei K, Yasukouchi S, Yoshikawa T, Furutani Y, Shimada E, Shinohara T, Shinozaki T, Matsuyama Y, Senzaki H, Nakanishi T : Predictors of long-term mortality among perioperative survivors of Fontan operation. Eur Heart J 2022 ; 43 : 2373-2384
 
2) Nii M, Inuzuka R, Inai K, et al : Incidence and Expected Probability of Liver Cirrhosis and Hepatocellular Carcinoma After Fontan Operation. Circulation 2021 ; 144 : 2043-2045
 
3) Inuzuka R, Nii M, Inai K, et al : Predictors of liver cirrhosis and hepatocellular carcinoma among perioperative survivors of the Fontan operation. Heart 2023 ; 109 : 276-282
 

【HEART' s Original】

P.679 掲載の参考文献
1) Bussani R, De-Giorgio F, Abbate A, Silvestri F : Cardiac metastases. J Clin Pathol 2007 ; 60 : 27-34
 
2) Tamura A, Matsubara O, Yoshimura N, et al : Cardiac metastasis of lung cancer. A study of metastatic pathways and clinical manifestations. Cancer 1992 ; 70 : 437-442
 
3) Abe S, Watanabe N, Ogura S, et al : Myocardial metastasis from primary lung cancer : myocardial infarction-like ECG changes and pathologic findings. Jpn J Med 1991 ; 30 : 213-218
 
4) 太宰康伸, 加藤市次郎, 末田章三, ほか : 急性心筋梗塞類似の心電図所見を示し, 心エコー上心筋内腫瘤を認めた肺癌の心筋転移の1例. 呼と循 1989 ; 37 : 461-465
 
5) 徳永隆成 : 心エコー上心臓粘液腫様の所見を呈した肺癌心筋転移の1例. 肺癌 2004 ; 44 : 19-24
 
6) Johnson DB, Balko JM, Compton ML, et al : Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016 ; 375 : 1749-1755
 
7) Mahmood SS, Fradley MG, Cohen JV, et al : Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 2018 ; 71 : 1755-1764
 
8) Wang DY, Salem JE, Cohen JV, et al : Fatal toxic effects associated with immune checkpoint inhibitors : a systematic review and meta-analysis. JAMA Oncol 2018 ; 4 : 1721-1728
 
9) Salem JE, Manouchehri A, Moey M, et al : Cardiovascular toxicities associated with immune checkpoint inhibitors : an observational, retrospective, pharmacovigilance study. Lancet Oncol 2018 ; 19 : 1579-1589
 
10) Tajiri K, Aonuma K, Sekine I : Immune checkpoint inhibitor-related myocarditis. Jpn J Clin Oncol 2018 ; 48 : 7-12
 
11) Pirozzi F, Poto R, Aran L, et al : Cardiovascular toxicity of immune checkpoint inhibitors : clinical risk factors. Curr Oncol Rep 2021 ; 23 : 13
PubMed
12) 大亀剛, 篠田明紀良, 重松義紀, ほか : Pembrolizumab初回投与後に劇症型心筋炎を発症して死亡した肺扁平上皮癌の1剖検例. 肺癌 2020 ; 60 : 335-340
 
13) Brahmer JR, Lacchetti C, Schneider BJ, et al ; National Comprehensive Cancer Network : Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy : American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018 ; 36 : 1714-1768
 
14) Bonaca MP, Olenchock BA, Salem JE, et al : Myocarditis in the setting of cancer therapeutics : proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation 2019 ; 140 : 80-91
 
15) Awadalla M, Mahmood SS, Groarke JD, et al : Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis. J Am Coll Cardiol 2020 ; 75 : 467-478
 
16) Zhang L, Zlotoff DA, Awadalla M, et al : Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis. Circulation 2020 ; 141 : 2031-2034
 
17) 日本循環器学会 : 2023年改訂版 心筋炎の診断・治療に関するガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2023/03/JCS2023_nagai.pdf (cited 2023 Mar 25)
 
18) Kwon HJ, Cote TR, Cuffe MS, et al : Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003 ; 138 : 807-811
 
P.682 掲載の参考文献
1) Palaskas N, Lopez-Mattei J, Durand JB, et al : Immune Checkpoint Inhibitor Myocarditis : Pathophysiological Characteristics, Diagnosis, and Treatment. J Am Heart Assoc 2020 ; 9 : e013757
 
2) 森真奈美, 鮎川宏之, 山田幸子, ほか : 原発性肺癌心筋転移に免疫チェックポイント阻害薬関連心筋炎を生じた1例. 心臓 2023 ; 55 : 672-680
 
3) 竹内慎一, 水谷晃輔, 飯沼光司, ほか : 腎細胞癌多発転移に対し集学的治療を行った後心臓転移を発症した1例. 泌尿器科紀要 2019 ; 65 : 197-201
 
4) Tang X, Zhou W, Huang D, et al : Anti-PD-1 Therapy-A Potential Treatment for Myocardial Metastasis From Nasopharyngeal Carcinoma : A Case Report. Front Immunol 2021 ; 12 : 688682
PubMed
5) 朝倉寿久, 中井康友, 岡利樹, ほか : 腎細胞癌心筋転移に対してニボルマブが有効であった1例. 泌尿器科紀要 2020 ; 66 : 225-228
 
6) Ansari J, Alhelali S, Albinmousa Z, et al : Rare Case of Intracardiac Renal Cell Carcinoma Metastasis with Response to Nivolumab : Case Report and Literature Review. Case Rep Oncol 2018 ; 11 : 861-870
 
7) Shirotake S, Umezawa Y, Okabe T, et al : Efficacy of nivolumab plus ipilimumab in a patient with renal cell carcinoma concomitant with cardiac metastasis : A case report. In Vivo 2020 ; 34 : 1475-1480
 
8) Pirozzi F, Poto R, Aran L, et al : Cardiovascular Toxicity of Immune Checkpoint Inhibitors : Clinical Risk Factors. Curr Oncol Rep 2021 ; 23 : 13
PubMed
9) Tajiri K, Ieda M : Cardiac Complications in Immune Checkpoint Inhibition Therapy. Front Cardiovasc Med 2019 ; 6 : 3
PubMed
10) Nakagomi Y, Tajiri K, Shimada S, et al : Immune Checkpoint Inhibitor-Related Myositis Overlapping With Myocarditis : An Institutional Case Series and a Systematic Review of Literature. Front Pharmacol 2022 ; 13 : 884776
 
P.688 掲載の参考文献
1) Global Burden of Disease Study 2013 Collaborators : Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013 : a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015 ; 386 : 743-800
 
2) Pollack A, Kontorovich AR, Fuster V, Dec GW : Viral myocarditis-diagnosis, treatment options, and current controversies. Nat Rev Cardiol 2015 ; 12 : 670-680
 
3) Su JR, McNeil MM, Welsh KJ, et al : Myopericarditis after vaccination, vaccine adverse event reporting system (VAERS), 1990-2018. Vaccine 2021 ; 39 : 839-845
 
4) Xie Y, Xu E, Bowe B, Al-Aly Z : Long-term cardiovascular outcomes of COVID-19. Nat Med 2022 ; 28 : 583-590
 
5) Hiroi Y, Ohtsu H, Uemura Y, et al : Cardiovascular complications of hospitalized patients with coronavirus disease 2019 in a Japanese registry in 2020. Circ J 2022 ; 86 : 464-471
 
6) Ling RR, Ramanathan K, Tan FL, et al : Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination : a systematic review and meta-analysis. Lancet Respir Med 2022 ; 10 : 679-688
 
7) 厚生労働省 : 厚生科学審議会 (予防接種・ワクチン分科会 副反応検討部会). https://www.mhlw.go.jp/stf/shingi/shingi-kousei_284075.html (cited 2023 May 03)
 
8) Heymans S, Cooper LT : Myocarditis after COVID-19 mRNA vaccination : clinical observations and potential mechanisms. Nat Rev Cardiol 2022 ; 19 : 75-77
 
9) Oster ME, Shay DK, Su JR, et al : Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA 2022 ; 327 : 331-340
 
10) Truong DT, Dionne A, Muniz JC, et al : Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults : Suspected Myocarditis After COVID-19 Vaccination. Circulation 2022 ; 145 : 345-356
 
11) Kyto V, Sipila J, Rautava P : The effects of gender and age on occurrence of clinically suspected myocarditis in adulthood. Heart 2013 ; 99 : 1681-1684
 
P.691 掲載の参考文献
1) Moreira ED Jr, Kitchin N, Xu X, et al : Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine. N Engl J Med 2022 ; 386 : 1910-1921
 
2) 甲斐久史. 新型コロナウイルス感染症と心筋炎. 日本医事新報2023 ; 5162 : 31-35
 
3) Block JP, Boehmer TK, Forrest CB, et al : Cardiac complications after SARS-CoV-2 infection and mRNA COVID-19 vaccination-PCORnet, United States, January 2021-January 2022. MMWR Morb Mortal Wkly Rep 2022 ; 71 : 517-523
 
4) 第82回厚生科学審議会予防接種・ワクチン分科会副反応検討部会, 令和4年度第8回薬事・食品衛生審議会薬事分科会医薬品等安全対策部会安全対策調査会. 2022年8月5日. https://www.cov19-vaccine.mhlw.go.jp/qa/uploads/0079_220805_1.pdf (cited 2023 May 31)
 
P.697 掲載の参考文献
1) Reynolds C, Tazelaar HD, Edwards WD : Calcified amorphous tumor of the heart (cardiac CAT). Hum Pathol 1997 ; 28 : 601-606
 
2) de Hemptinne Q, de Canniere D, Vandenbossche JL, Unger P : Cardiac calcified amorphous tumor : A systematic review of the literature. Int J Cardiol Heart Vasc 2015 ; 7 : 1-5
 
3) Yoshimura S, Kawano H, Minami T, et al : Cardiac Calcified Amorphous Tumors in a Patient with Hemodialysis for Diabatic Nephropathy. Intern Med 2017 ; 56 : 3057-3060
 
4) Watanabe H, Shimbo M, Ito H : A cardiac calcified amorphous tumor associated with end-stage renal desease : an emerging disease concept. Intern Med 2017 ; 56 : 2967-2968
 
5) Kubota H, Fujioka Y, Yoshino H, et al : Cardiac swinging calcified amorphous tumors in end-stage renal failure patients. Ann Thorac Surg 2010 ; 90 : 1692-1694
 
6) 高橋雄, 新野哲也 : 脳梗塞を契機に発見されたCAT (Calcified amorphous tumor) の1例. 日心外会誌 2020 ; 49 : 16-20
 
7) 木村倫子, 春田裕典, 玉城貴啓, ほか : 脳梗塞を契機に発見されたCalcified Amorphous Tumorの1 症例. 心臓 2017 : 49 : 502-507
 
8) 衣笠由祐, 手嶋英樹, 井上善紀, ほか : 僧帽弁穿孔, 腱索断裂を引き起こしたと考えられたcalcified amorphous tumorの1例. 日心外会誌 2019 ; 48 : 259-262
 
9) 佐藤文昭, 山内孝, 寺澤史明, ほか : 急速に形成された維持透析患者におけるcalcified amorphous tumorの1例. 心臓 2017 ; 49 : 141-145
 
10) 神尾多喜浩, 古川優貴, 富田文子, ほか : 急速に発育し多発性脳梗塞をきたしたcalcified amorphous tumorの1例. 診断病理 2018 : 35 : 223-227
 
11) 四方典裕, 室生卓, 中島博之, ほか : 急速な経過で僧帽弁に腫瘤形成を来したcalcified amorphous tumorの1例. 日心臓病会誌 2011 ; 6 : 77-80
 
12) Fealey ME, Edwards WD, Reynold C, et al : Recurrent cardiac calcified amorphous tumor : the CAT had a kitten. Cardiovasc Pathol 2007 ; 16 : 115-118
 
P.699 掲載の参考文献
1) Reynolds C, Tazelaar HD, Edwards WD : Calcified amorphous tumor of the heart (cardiac CAT). Hum Pathol 1997 ; 28 : 601-606
 
2) Ushioda R, Shirasaka T, Kikuchi S, et al : Calcified amorphous tumor located on a severely calcified mitral annulus in a patient with normal renal function. J Surg Case Rep 2022 ; 2022 : rjab608
 
3) Kubota H, Fujioka Y, Yoshino H, et al : Cardiac swinging calcified amorphous tumors in end-stage renal failure patients. Ann Thorac Surg 2010 ; 90 : 1692-1694
 
4) Ikeno Y, Mukohara N, Fukumura Y, et al : Outcomes of valve replacement with mechanical prosthesis versus bioprosthesis in dialysis patients : A 16-year multicenter experience. J Thorac Cardiovasc Surg 2019 ; 158 : 48-56.e4
 
P.700 掲載の参考文献
1) Reynolds C, Tazelaar HD, Edwards WD : Calcified amorphous tumor of the hear (t cardiac CAT). Hum Pathol 1997 ; 28 : 601-606
 
2) de Hemptinne Q, de Canniere D, Vandenbossche JL, Unger P : Cardiac calcified amorphous tumor : A systematic review of the literature. Int J Cardiol Heart Vasc 2015 ; 7 : 1-5
 
3) Watanabe H, Shimbo M, Ito H : A cardiac calcified amorphous tumor associated with end-stage renal disease : an emerging disease concept. Intern Med 2017 ; 56 : 2967-2968
 
P.708 掲載の参考文献
1) Cardinale D, Colombo A, Lamantia G, et al : Anthracycline-induced cardiomyopathy : clinial relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010 ; 55 : 213-220
 
2) Thavendiranathan P, Poulin F, Lim KD, et al : Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy : asystematic review. J Am Coll Cardiol 2014 ; 63 : 2751-2768
 
3) 日本循環器学会 : 2021年改訂版 循環器超音波検査の適応と判読ガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Ohte.pdf (cited 2023 May 01)
 
4) Plana JC, Galderisi M, Barac A, et al : Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy : a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014 ; 27 : 911-939
 
5) Hor KN, Baumann R, Pedrizzetti G, et al : Magnetic resonance derived myocardial strain assessment using feature tracking. J Vis Exp 2011 ; (48) : 2356
PubMed
6) Salem JE, Manouchehri A, Moey M, et al : Cardiovascular toxicities associated with immune checkpoint inhibitors : an observational, retrospective, pharmacovigilance study. Lancet Oncol 2018 ; 19 : 1579-1589
 
7) Bonaca MP, Olenchock BA, Salem JE, et al : Myocarditis in the Setting of Cancer Therapeutics : Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology. Circulation 2019 ; 140 : 80-91
 
8) Brahmer JR, Lacchetti C, Schneider BJ, et al : Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy : American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018 ; 36 : 1714-1768
 
9) Thompson JA, Schneider BJ, Brahmer J, et al : NCCN Guidelines Insights : Management of Immunotherapy-Related Toxicities, Version 1. 2020. J Natl Compr Canc Netw 2020 ; 18 : 230-241
 
10) Johnson DB, Balko JM, Compton ML, et al : Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med 2016 ; 375 : 1749-1755
 
11) Hu K, Liu D, Herrmann S, et al : Clinical implication of mitral annular plane systolic excursion for patients with cardiovascular disease. Eur Heart J Cardiovasc Imaging 2013 ; 14 : 205-212
 
12) Stanton T, Leano R, Marwick TH : Prediction of all-cause mortality from global longitudinal speckle strain : comparison with ejection fraction and wall motion scoring. Circ Cardiovasc Imaging 2009 ; 2 : 356-364
 
13) Mahmood SS, Fradley MG, Cohen JV, et al : Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol 2018 ; 71 : 1755-1764
 
14) Awadalla M, Mahmood SS, Groarke JD, et al : Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. J Am Coll Cardiol 2020 ; 75 : 467-478
 
15) Higgins AY, Arbune A, Soufer A, et al : Left ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity. PLoS One 2021 ; 16 : e0246764
PubMed
16) Houbois CP, Nolan M, Somerset E, et al : Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer : Comparison With Echocardiography. JACC Cardiovasc Imaging 2021 ; 14 : 962-974
 
17) 日本心エコー図学会 : 抗がん剤治療関連心筋障害の診療における心エコー図検査の手引. http://www.jse.gr.jp/onco2020.pdf (cited 2023 May 01)
 
18) Lyon AR, Lopez-Fernandez T, Couch LS, et al ; ESC Scientific Document Group : 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022 ; 43 : 4229-4361
 
P.709 掲載の参考文献
1) Brahmer JR, Lacchetti C, Schneider BJ, et al : Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy : American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018 ; 36 : 1714-1768
 
2) Lyon AR, Lopez-Fernandez T, Couch LS, et al : 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022 ; 43 : 4229-4361
 
3) Negishi T, Thavendiranathan P, Penicka M, et al : Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy : 3-Year Results of the SUCCOUR Trial. JACC Cardiovasc Imaging 2023 ; 16 : 269-278
 

【研究会】

P.718 掲載の参考文献
1) 新型コロナウイルス感染症患者診療の手引き 第5版. https://www.mhlw.go.jp/content/000785119.pdf (cited 2023 Feb 12)
 
2) Lodigiani C, Iapichino G, Carenzo L, et al : Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res 2020 ; 191 : 9-14
 
3) Bilaloglu S, Aphinyanaphongs Y, Jones S, et al : Thrombosis in hospitalized patients with COVID-19 in a New York City health system. JAMA 2020 ; 324 : 799-801
 
4) Yamashita Y, Yamada N, Mo M : The primary prevention of venous thromboembolism in patients with COVID-19 in Japan : current status and future perspective. Ann Vasc Dis 2021 ; 14 : 1-4
PubMed
5) Horiuchi H, Morishita E, Urano T, Yokoyama K ; Questionnaire-survey joint team on the COVID-19-related thrombosis : COVID-19-related thrombosis in Japan : final report of a questionnaire-based survey in 2020. J Atheroscler Thromb 2021 ; 28 : 406-416
 
6) Yamashita Y, Maruyama Y, Satokawa H, et al : Incidence and clinical features of venous thromboembolism in hospitalized patients with coronavirus disease 2019 (COVID-19) in Japan. Circ J 2021 ; 85 : 2208-2214
 
7) Nishimoto Y, Yachi S, Yakeyama M, et al : The current status of thrombosis and anticoagulation therapy in patients with COVID-19 in Japan : From the CLOT-COVID study. J Cardiol 2022 ; 80 : 285-291
 
8) National Institutes of Health : COVID-19 treatment guidelines. Antithrombotic Therapy in Patients With COVID-19. https://www.covid19treatmentguidelines.nih.gov/therapies/antithrombotic-therapy/ (cited 2023 Feb 19)
 
9) 日本静脈学会/肺塞栓症研究会/日本血管外科学会/日本脈管学会/日本循環器学会 : 新型コロナウイルス感染症 (COVID-19) における血栓症予防および抗凝固療法の診療指針 (version 4.0). https://js-phlebology.jp/wp/wp-content/uploads/2022/06/新型コロナウイルス感染症(COVID-19)における血栓症予防および抗凝固療法の診療指針Ver.4.0.pdf (cited 2023 Feb 19)
 
P.724 掲載の参考文献
1) Spyropoulos AC, Levy JH, Ageno W, et al ; Subcommittee on Perioperative, Critical Care Thrombosis, Haemostasis of the Scientific, Standardization Committee of the International Society on Thrombosis and Haemostasis : Scientific and Standardization Committee communication : Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020 ; 18 : 1859-1865
 
2) Lodigiani C, Iapichino G, Carenzo L, et al ; Humanitas COVID-19 Task Force : Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res 2020 ; 191 : 9-14
 
3) Cui S, Chen S, Li X, et al : Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020 ; 18 : 1421-1424
 
4) Klok FA, Kruip MJHA, van der Meer NJM, et al : Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020 ; 191 : 145-147
 
5) Wichmann D, Sperhake JP, Lutgehetmann M, et al : Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 : A Prospective Cohort Study. Ann Intern Med 2020 ; 173 : 268-277
 
6) Malas MB, Naazie IN, Elsayed N, et al : Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality : A systematic review and meta-analysis. EClinicalMedicine 2020 ; 29 : 100639
PubMed
7) Jimenez D, Garcia-Sanchez A, Rali P, et al : Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019 : A Systematic Review and Meta-analysis. Chest 2021 ; 159 : 1182-1196
 
8) Kahn SR, Lim W, Dunn AS, et al ; Prevention of VTE in nonsurgical patients : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012 ; 141 (2 Suppl) : e195S-e226S
 
9) Kollias A, Kyriakoulis KG, Dimakakos E, et al : Thromboembolic risk and anticoagulant therapy in COVID-19 patients : emerging evidence and call for action. Br J Haematol 2020 ; 189 : 846-847
 
10) NIH Coronavirus Disease 2019 (COVID-19) Treatment Guidelines : Therapeutic Management of Hospitalized Adults With COVID-19. https://files.covid19treatmentguidelines.nih.gov/guidelines/section/section_100.pdf?%20msclkid=e7046af8ceb911ecb34656ef2a13b711
 
11) Cuker A, Tseng EK, Nieuwlaat R, et al : American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 : January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients. Blood Adv 2022 ; 6 : 4915-4923
 
12) 日本循環器学会 : 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/09/JCS2017_ito.pdf
 
13) Chiang CE, Wang KL, Lip GY : Stroke prevention in atrial fibrillation : an Asian perspective. Thromb Haemost 2014 ; 111 : 789-797
 
14) 日本静脈学会 : 「新型コロナウイルス感染症 (COVID-19) と静脈血栓塞栓症」の緊急のアンケート結果について. https://js-phlebology.jp/?p=3326
 
15) Yamashita Y, Yamada N, Mo M : The Primary Prevention of Venous Thromboembolism in Patients with COVID-19 in Japan : Current Status and Future Perspective. Ann Vasc Dis 2021 ; 14 : 1-4
PubMed
16) Yamashita Y, Hara N, Obana M, et al : Clinical Features of Venous Thromboembolism in Patients With Coronavirus Disease 2019 (COVID-19) in Japan - A Case Series Study. Circ J 2021 ; 85 : 309-313
 
17) 厚生労働省難治性疾患政策研究事業「血液凝固異常症等に関する研究」班, 日本血栓止血学会, 日本動脈硬化学会, 合同COVID-19関連血栓症アンケート調査チーム : COVID-19関連血栓症アンケート調査結果報告. http://www.jsth.org/wordpress/wp-content/uploads/2020/12/COVID-19関連血栓症アンケート報告書ホームページ掲載版.pdf
 
18) Horiuchi H, Morishita E, Urano T, Yokoyama K ; Questionnaire-survey Joint Team on The COVID-19-related thrombosis : COVID-19-Related Thrombosis in Japan : Final Report of a Questionnaire-Based Survey in 2020. J Atheroscler Thromb 2021 ; 28 : 406-416
 
19) Yamashita Y, Maruyama Y, Satokawa H, et al : Incidence and Clinical Features of Venous Thromboembolism in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) in Japan. Circ J 2021 ; 85 : 2208-2214
 
20) Fujiwara S, Nakajima M, Kaszynski RH, et al : Prevalence of thromboembolic events and status of prophylactic anticoagulant therapy in hospitalized patients with COVID-19 in Japan. J Infect Chemother 2021 ; 27 : 869-875
 
21) Oba S, Hosoya T, Amamiya M, et al : Arterial and Venous Thrombosis Complicated in COVID-19 : A Retrospective Single Center Analysis in Japan. Front Cardiovasc Med 2021 ; 8 : 767074
 
22) Nishimoto Y, Yachi S, Takeyama M, et al ; CLOT-COVID Study Investigators : The current status of thrombosis and anticoagulation therapy in patients with COVID-19 in Japan : From the CLOT-COVID study. J Cardiol 2022 ; 80 : 285-291
 
23) Yamashita Y, Yachi S, Takeyama M, et al ; CLOT-COVID Study Investigators : Influence of sex on development of thrombosis in patients with COVID-19 : From the CLOT-COVID study. Thromb Res 2022 ; 213 : 173-178
 
24) Ikeda N, Yachi S, Takeyama M, et al ; CLOT-COVID Study Investigators : D-Dimer Values and Venous Thromboembolism in Patients With COVID-19 in Japan-From the CLOT-COVID Study. Circ Rep 2022 ; 4 : 215-221
 
25) 厚生労働省 : 新型コロナウイルス感染症 診療の手引き 第7.2版. https://www.mhlw.go.jp/content/000936655.pdf
 
26) Moores LK, Tritschler T, Brosnahan S, et al : Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019 : CHEST Guideline and Expert Panel Report. Chest 2020 ; 158 : 1143-1163
 
27) Cuker A, Tseng EK, Nieuwlaat R, et al : American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 : May 2021 update on the use of intermediate intensity anticoagulation in critically ill patients. Blood Adv 2021 ; 5 : 3951-3959
 
28) Lavinio A, Ercole A, Battaglini D, et al : Safety profile of enhanced thromboprophylaxis strategies for critically ill COVID-19 patients during the first wave of the pandemic : observational report from 28 European intensive care units. Crit Care 2021 ; 25 : 155
PubMed
29) INSPIRATION Investigators, Sadeghipour P, Talasaz AH, et al : Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit : The INSPIRATION Randomized Clinical Trial. JAMA 2021 ; 325 : 1620-1630
PubMed
30) Lopes RD, de Barros E Silva PGM, Furtado RHM, et al ; ACTION Coalition COVID-19 Brazil IV Investigators : Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION) : an open-label, multicentre, randomised, controlled trial. Lancet 2021 ; 397 : 2253-2263
 
31) ATTACC Investigators ; ACTIV-4a Investigators ; REMAP-CAP Investigators, et al : Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med 2021 ; 385 : 790-802
 
32) REMAP-CAP Investigators ; ACTIV-4a Investigators ; ATTACC Investigators, et al : Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N Engl J Med 2021 ; 385 : 777-789
 
33) Sholzberg M, Tang GH, Rahhal H, et al ; RAPID trial investigators : Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital : RAPID randomised clinical trial. BMJ 2021 ; 375 : n2400
 
34) Spyropoulos AC, Goldin M, Giannis D, et al ; HEP-COVID Investigators : Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19 : the HEP-COVID randomized clinical trial. JAMA Intern Med 2021 ; 181 : 1612-1620
PubMed
35) Marcos-Jubilar M, Carmona-Torre F, Vidal R, et al ; BEMICOP Investigators : Therapeutic versus prophylactic bemiparin in hospitalized patients with nonsevere COVID-19 pneumonia (BEMICOP study) : an open-label, multicenter, randomized, controlled trial. Thromb Haemost 2022 ; 122 : 295-299
 
36) 日本集中治療医学会 : 日本版敗血症診療ガイドライン 2020 (J-SSCG2020) 特別編COVID-19薬物療法に関するRapid/Living recommendations 第4.3版. https://www.jsicm.org/news/upload/J-SSCG2020_COVID-19_1_ver.4.3.0.pdf
 
37) Musoke N, Lo KB, Albano J, et al : Anticoagulation and bleeding risk in patients with COVID-19. Thromb Res 2020 ; 196 : 227-230
 
38) Shalhoub J, Lawton R, Hudson J, et al ; GAPS trial investigators : Graduated compression stockings as adjuvant to pharmaco-thromboprophylaxis in elective surgical patients (GAPS study) : randomised controlled trial. BMJ 2020 ; 369 : m1309
 
39) Suna K, Herrmann E, Kroger K, et al : Graduated compression stockings in the prevention of postoperative pulmonary embolism. A propensity-matched retrospective case-control study of 24273 patients. Ann Med Surg (Lond) 2020 ; 56 : 203-210
 
40) Arabi YM, Al-Hameed F, Burns KEA, et al ; Saudi Critical Care Trials Group : Adjunctive Intermittent Pneumatic Compression for Venous Thromboprophylaxis. N Engl J Med 2019 ; 380 : 1305-1315
 
41) 日本静脈学会 : ビデオ 弾性ストッキングの着用方法. https://js-phlebology.jp/movie/es.mp4
 
42) 日本静脈学会 : 新型コロナウイルス感染者で宿泊療養や自宅療養をされている方および報道機関の皆様へのお願い. https://js-phlebology.jp/?p=3897
 
P.731 掲載の参考文献
1) Guan WJ, Ni ZY, Hu Y, et al ; China Medical Treatment Expert Group for Covid-19 : Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020 ; 382 : 1708-1720
 
2) Huang C, Wang Y, Li X, et al : Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020 ; 395 : 497-506
 
3) Wichmann D, Sperhake JP, Lutgehetmann M, et al : Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 : A Prospective Cohort Study. Ann Intern Med 2020 ; 173 : 268-277
 
4) Chiang CE, Wang KL, Lip GY : Stroke prevention in atrial fibrillation : an Asian perspective. Thromb Haemost 2014 ; 111 : 789-797
 
5) Yamashita Y, Yamada N, Mo M : The primary prevention of venous thromboembolism in patients with COVID-19 in Japan : current status and future perspective. Ann Vasc Dis 2021 ; 14 : 1-4
PubMed
6) 日本静脈学会 : 「新型コロナウイルス感染症 (COVID-19) と静脈血栓塞栓症」の緊急のアンケート結果について. https://js-phlebology.jp/?p=3326
 
7) Nishimoto Y, Yachi S, Takeyama M, et al : The current status of thrombosis and anticoagulation therapy in patients with COVID-19 in Japan : From the CLOT-COVID study. J Cardiol 2022 ; 80 : 285-291
 
8) 厚生労働省 : 新型コロナウイルス感染症 診療の手引き第5.2版. https://www.mhlw.go.jp/content/000815065.pdf
 
9) Ikeda N, Yachi S, Takeyama M, et al : D-Dimer Values and Venous Thromboembolism in Patients With COVID-19 in Japan - From the CLOT-COVID Study. Circ Rep 2022 ; 4 : 215-221
 
10) Yamashita Y, Yachi S, Takeyama M, et al : Influence of sex on development of thrombosis in patients with COVID-19 : From the CLOT-COVID study. Thromb Res 2022 ; 213 : 173-178
 
11) Yamashita Y, Yachi S, Takeyama M, et al : Significant Impact of Age on Mortality and Non-significant Impact of Age on Thrombosis and Major Bleeding in Patients with COVID-19 : From the CLOT-COVID Study. J Atheroscler Thromb 2022 Jul 29. doi : 10.5551/jat.63702.
 
12) Ikeda S, Ueno Y, Maemura K, et al : Association Between the Development of Thrombosis and Worsening of Disease Severity in Patients With Moderate COVID-19 on Admission-From the CLOT-COVID Study. Circ J 2023 ; 87 : 448-455
 
13) Yamashita Y, Yachi S, Takeyama M, et al : Therapeutic-Dose vs. Prophylactic-Dose Anticoagulation Therapy for Critically Ill Patients With COVID-19 in a Practice-Based Observational Study. Circ J 2022 ; 86 : 1137-1142
 
14) Nakamura J, Tujino I, Yachi S, et al : Incidence, risk factors, and clinical impact of major bleeding in hospitalized patients with COVID-19 : a sub-analysis of the CLOT-COVID Study. Thromb J 2022 ; 20 : 53
 
15) 新型コロナウイルス感染症 (COVID-19) における静脈血栓塞栓症予防の診療指針 2021年1月25日 (Version 1.0). http://j-ca.org/wp/wp-content/uploads/2021/01/20210125%E3%80%80新型コロナウイルス感染症(COVID-19)における静脈血栓塞栓症予防の指針%E3%80%80ver1.0%E3%80%80PDF.pdf
 
16) 新型コロナウイルス感染症 (COVID-19) における静脈血栓塞栓症予防の診療指針 2021年4月5日 (Version 2.0). https://www.jstage.jst.go.jp/article/phlebol/32/1/32_21-16/_article/-char/ja
 
17) 新型コロナウイルス感染症 (COVID-19) における静脈血栓塞栓症予防および抗凝固療法の診療指針 2021年10月5日 (Version 3.0). https://js-phlebology.jp/wp/wp-content/uploads/2021/10/20211005新型コロナウイルス感染症(COVID-19)における静脈血栓塞栓症予防の診療指針%E3%80%80.pdf
 
18) 新型コロナウイルス感染症 (COVID-19) における血栓症予防および抗凝固療法の診療指針 2022年6月13日 (Version 4.0). https://www.j-circ.or.jp/cms/wp-content/uploads/2022/06/JCS_notice_20220627_1.pdf
 
19) 新型コロナウイルス感染症 (COVID-19) における血栓症予防および抗凝固療法の診療指針 2023年2月25日 (Version 4.1). http://www.ja-sper.org/ja/file/pdf/coronavirus_prevention_ver4.1.pdf
 
20) INSPIRATION Investigators ; Sadeghipour P, Talasaz AH, Rashidi F, et al : Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit : The INSPIRATION Randomized Clinical Trial. JAMA 2021 ; 325 : 1620-1630
PubMed
21) Lopes RD, de Barros E Silva PGM, Furtado RHM, et al : Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION) : an open-label, multicentre, randomised, controlled trial. Lancet 2021 ; 397 : 2253-2263
 
22) REMAP-CAP Investigators ; ACTIV-4a Investigators ; ATTACC Investigators, et al : Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N Engl J Med 2021 ; 385 : 777-789
 
23) ATTACC Investigators ; ACTIV-4a Investigators ; REMAP-CAP Investigators, et al : Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med 2021 ; 385 : 790-802
 
24) Sholzberg M, Tang GH, Rahhal H, et al ; RAPID trial investigators : Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital : RAPID randomised clinical trial. BMJ 2021 ; 375 : n2400
 
25) Spyropoulos AC, Goldin M, Giannis D, et al ; HEP-COVID Investigators : Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19 : the HEP-COVID randomized clinical trial. JAMA Intern Med 2021 ; 181 : 1612-1620
PubMed
P.737 掲載の参考文献
1) Mehta P, McAuley DF, Brown M, et al ; HLH Across Speciality Collaboration, UK : COVID-19 : consider cytokine storm syndromes and immunosuppression. Lancet 2020 ; 395 : 1033-1034
 
2) Zhang Y, Xiao M, Zhang S, et al : Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 2020 ; 382 : e38
 
3) Kwaan HC, Lindholm PF : The Central Role of Fibrinolytic Response in COVID-19-A Hematologist's Perspective. Int J Mol Sci 2021 ; 22 : 1283
PubMed
4) Kruse JM, Magomedov A, Kurreck A, et al : Thromboembolic complications in critically ill COVID-19 patients are associated with impaired fibrinolysis. Crit Care 2020 ; 24 : 676
PubMed
5) Ladikou EE, Sivaloganathan H, Milne KM, et al : Von Willebrand factor (vWF) : marker of endothelial damage and thrombotic risk in COVID-19? Clin Med (Lond) 2020 ; 20 : e178-e182
 
6) Zuo Y, Estes SK, Ali RA, et al : Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med 2020 ; 12 : eabd3876
PubMed
7) Jhaveri KD, Meir LR, Flores Chang BS, et al : Thrombotic microangiopathy in a patient with COVID-19. Kidney Int 2020 ; 98 : 509-512
 
8) Guarneri C, Rullo EV, Pavone P, et al : Silent COVID-19 : what your skin can reveal. Lancet Infect Dis 2021 ; 21 : 24-25
 
9) Laurence J, Mulvey JJ, Seshadri M, et al : Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19. Clin Immunol 2020 ; 219 : 108555
PubMed
10) Gardner AJ, Kirkin DJ, Rodriguez-Villar S, et al : Antithrombin III deficiency-induced coagulopathy in the context of COVID-19 : a case series. Br J Haematol 2021 ; 194 : 1007-1009
 
11) de la Morena-Barrio ME, Bravo-Perez C, de la Morena-Barrio B, et al : A pilot study on the impact of congenital thrombophilia in COVID-19. Eur J Clin Invest 2021 ; 51 : e13546
PubMed
12) Umetsu M, Kanamori H, Murakami K, et al ; The CLOT-COVID Study Investigators : Clinical Features Comparing Arterial Thrombosis and Venous Thromboembolism in Hospitalized Patients with COVID-19 : Result from the CLOT-COVID Study. Ann Vascul Dis 2023 May 19. doi : 10.3400/avd.oa.22-00112
 
13) Katsoularis I, Fonseca-Rodriguez O, Farrington P, et al : Risks of deep vein thrombosis, pulmonary embolism, and bleeding after COVID-19 : nationwide self-controlled cases series and matched cohort study. BMJ 2022 ; 377 : e069590
PubMed
P.742 掲載の参考文献
1) Meyer G. Vicaut E, Danays T, et al ; PEITHO Investigators : Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism. N Engl J Med 2014 ; 370 : 1402-1411
 
2) 日本循環器学会 : 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/09/JCS2017_ito.pdf
 
3) Konstantinides SV, Meyer G, Becattini C, et al ; ESC Scientific Document Group : 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020 ; 41 : 543-603
 
4) Jaber WA, Fong PP, Weisz G, et al ; Acute pulmonary embolism : with an emphasis on an interventional approach. J Am Coll Cardiol 2016 ; 67 : 991-1002
 
5) Niwa A, Nakamura M, Harada N, Musha T : Observational investigation of thrombolysis with the tissue-type plasminogen activator monteplase for acute pulmonary embolism in Japan. Circ J 2012 ; 76 : 2471-2480
 
6) Sharifi M, Berger J, Beeston P, et al : Pulseless electrical activity in pulmonary embolism treated with thrombolysis (from the "PEAPETT" study). Am J Emerg Med 2016 ; 34 : 1963-1967
 
P.748 掲載の参考文献
1) EINSTEIN-PE Investigators : Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012 ; 366 : 1287-1297
 
2) Riedel M, Stanek V, Widimsky J, Prerovsky I : Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest 1982 ; 81 : 151-158
 
3) Jamieson SW, Kapelanski DP, Sakakibara N, et al : Pulmonary endarterectomy : experience and lessons learned in 1,500 cases. Ann Thorac Surg 2003 : 76 : 1457-1462
 
4) Feinstein JA, Goldhaber SZ, Lock JE, et al : Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension. Circulation 2001 : 103 : 10-13
 
5) Bunclark K, Newnham M, Chiu YD, et al : A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension. J Thromb Haemost 2020 : 18 : 114-122
 
6) Jeong I, Alotaibi M, Fernandes TM, et al : Direct oral anticoagulants in patients with chronic thromboembolic pulmonary hypertension and the presence of recent thrombus during pulmonary endarterectomy. Pulm Circ 2022 : 12 : e12110
PubMed
7) Goto E, Horinaka S, Ishimitsu T, Kato T : Factor Xa inhibitors in clinical practice : Comparison of pharmacokinetic profiles. Drug Metab Pharmacokinet 2020 : 35 : 151-159
 
8) Mueck W, Stampfuss J, Kubitza D, Becka M : Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 2014 : 53 : 1-16
 
9) Ikeda N, Amemiya K, Sato S, et al : Evolution of patients with chronic thromboembolic pulmonary hypertension treated by balloon pulmonary angioplasty, according to their anticoagulant regimens. Heart Vessels 2021 : 36 : 910-915
 
P.753 掲載の参考文献
1) 日本循環器学会 : 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/09/JCS2017_ito.pdf
 
2) Konstantinides SV, Meyer G, Becattini C, et al ; ESC Scientific Document Group : 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020 ; 41 : 543-603
 
3) Kearon C, Akl EA, Ornelas J, et al : Antithrombotic Therapy for VTE Disease : CHEST Guideline and Expert Panel Report. Chest 2016 ; 149 : 315-352
 
4) Zondag W, Mos IC, Creemers-Schild D, et al ; Hestia Study Investigators : Outpatient treatment in patients with acute pulmonary embolism : The Hestia Study. J THromb Haemost 2011 ; 9 : 1500-1507
 
5) Brandjes DP, Heijboer H, Buller HR, et al : Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992 ; 327 : 1485-1489
 
6) Cheung YW, Middeldorp S, Prins MH, et al ; Einstein PTS Investigators Group : Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thromb Haemost 2016 ; 116 : 733-738
PubMed
7) Konstantinides SV, Torbicki A, Agnelli G, et al ; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) : 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014 ; 35 : 3033-3069
 
8) Levine MN, Hirsh J, Gent M, et al : Optimal duration of oral anticoagulant therapy : a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995 ; 74 : 606-611
 
P.758 掲載の参考文献
1) Sessa C, Nicolini P, Perrin M, et al : Management of symptomatic and asymptomatic popliteal venous aneurysms : a retrospective analysis of 25 patients and review of the literature. J Vasc Surg 2000 ; 32 : 902-912
 
2) Cox MW, Krishnan S, Aidinian G : Fatal pulmonary embolus associated with asymptomatic popliteal venous aneurysm. J Vasc Surg 2008 ; 48 : 1040
PubMed
3) Volteas SK, Labropoulos N, Nicolaides AN : The management of venous aneurysm of the lower extremities. Panminerva Med 1998 ; 40 : 89-93
 
4) Lankeit M, Jimenez D, Kostrubiec M, et al : Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism. Eur Respir J 2014 ; 43 : 1669-1677
 
5) 日本循環器学会 : 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/09/JCS2017_ito.pdf
 
6) 日本循環器学会/日本不整脈心電学会 : 2022年改訂版 不整脈の診断とリスク評価に関するガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2022/03/JCS2022_Takase.pdf
 
7) Prandoni P, Lensing AW, Prins MH, et al ; PESIT Investigators : Prevalence of Pulmonary Embolism among Patients Hospitalized for Syncope. N Engl J Med 2016 ; 375 : 1524-1531
 
8) Meyer G, Vicaut E, Danays T, et al ; PEITHO Investigators : Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 2014 ; 370 : 1402-1411
 
9) Noppeney T, Kopp R, Pfister K, et al : Treatment of popliteal vein aneurysms. J Vasc Surg Venous Lymphat Disord 2019 ; 7 : 535-542
 
10) Norimatsu T, Aramoto H : Surgical repair for popliteal venous aneurysm causing severe or recurrent pulmonary thromboembolism : three case reports. Ann Vasc Dis 2015 ; 8 : 56-58
PubMed
11) 長谷川雅彦, 中田俊介, 小西康信 : 肺血栓塞栓症を発症した膝窩静脈性血管瘤の1例. 日臨外会誌 2021 ; 82 : 663-667
 
12) 大住幸司, 関本康人, 長崎和仁 : 術後再発をきたした膝窩静脈静脈性血管瘤の1例. 日血管外会誌 2018 ; 27 : 457-459
 
P.762 掲載の参考文献
1) Nakamura M, Fujioka H, Yamada N, et al : Clinical characteristics of acute pulmonary thromboembolism in Japan : results of a multicenter registry in the Japanese Society of Pulmonary Embolism Research. Clin Cardiol 2001 ; 24 : 132-138
 
2) 樗木等, 堺正人, 赤塚裕, ほか : 急性肺塞栓症に対する診断の工夫と治療方針. 静脈学 1995 ; 6 : 307-311
 
3) Hashiba K, Okuda J, Maejima N, et al : Percutaneous cardiopulmonary support in pulmonary embolism with cardiac arrest. Resuscitation 2012 ; 83 : 183-187
 
4) Ghoreishi M, DiChiacchio L, Pasrija C, et al : Predictors of Recovery in Patients Supported With Venoarterial Extracorporeal Membrane Oxygenation for Acute Massive Pulmonary Embolism. Ann Thorac Surg 2020 ; 110 : 70-75
 
P.767 掲載の参考文献
1) Buller HR, Davidson BL, Decousus H, et al ; Matisse Investigators : Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003 ; 349 : 1695-1702
 
2) Agnelli G, Bergqvist D, Cohen AT, et al : Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005 ; 92 : 1212-1220
 
3) Hokusai-VTE Investigators ; Buller HR, Decousus H, Grosso MA, et al : Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013 ; 369 : 1406-1415
 
4) EINSTEIN Investigators ; Bauersachs R, Berkowitz SD, Brenner B, et al : Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010 ; 363 : 2499-2510
 
5) Agnelli G, Buller HR, Cohen A, et al ; AMPLIFY Investigators : Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013 ; 369 : 799-808
 
6) Shimizu K, Iiduka T, Sato S, et al : The clinical course of symptomatic deep vein thrombosis after 3 months of anticoagulant therapy using fondaparinux/edoxaban or fondaparinux/vitamin K antagonist. Ther Clin Risk Manag 2018 ; 14 : 377-383
PubMed
7) 日本循環器学会 : 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/09/JCS2017_ito.pdf
 
8) Nakamura M, Wang YQ, Wang C, et al : Efficacy and safety of edoxaban for treatment of venous thromboembolism : a subanalysis of East Asian patients in the Hokusai-VTE trial. J Thromb Haemost 2015 ; 13 : 1606-1614
 
9) Yamashita Y, Morimoto T, Amano H, et al ; COMMAND VTE Registry Investigators : Anticoagulation Therapy for Venous Thromboembolism in the Real World-From the COMMAND VTE Registry. Circ J 2018 : 82 : 1262-1270
 
P.770 掲載の参考文献
1) 北川一夫 : Embolic Stroke of Undetermined Sources (ESUS) の病態. 神経治療2016 ; 33 : 382-386
 
2) Hart RG, Diener HC, Coutts SB, et al ; ESUS International Working Group : Embolic strokes of undetermined source : the case for a new clinical construct. Lancet Neurol 2014 ; 13 : 429-438
 
3) 井口保之, 岩間亨, 大木宏一, ほか : 日本脳卒中学会, 日本循環器学会, 日本心血管インターベンション治療学会 潜因性脳梗塞に対する経皮的卵円孔開存閉鎖術の手引き (2019年5月)
 
4) Samuel S, Reddy ST, Parsha KN, et al : Routine surveillance of pelvic and lower extremity deep vein thrombosis in stroke patients with patent foramen ovale. J Thromb Thrombolysis 2021 ; 51 : 1150-1156
 
5) Kent DM, Ruthazer R, Weimar C, et al : An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology 2013 ; 81 : 619-625
 
6) Mas JL, Derumeaux G, Guillon B, et al ; CLOSE Investigators : Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. N Engl J Med 2017 ; 377 : 1011-1021
 
7) Saver JL, Carroll JD, Thaler DE, et al ; RESPECT Investigators : Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. N Engl J Med 2017 ; 377 : 1022-1032
PubMed
8) Sonderpaard L, Kasner SE, Rhodes JF, et al ; Gore REDUCE Clinical Study Investigators : Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke. N Engl J Med 2017 ; 377 : 1033-1042
 
9) Mir H, Siemieniuk RCA, Ge L, et al : Patent foramen ovale closure, antiplatelet therapy or anticoagulation in patients with patent foramen ovale and cryptogenic stroke : a systematic review and network meta-analysis incorporating complementary external evidence. BMJ Open 2018 ; 8 : e023761
PubMed
10) Kasner SE, Swaminathan B, Lavados P, et al ; NAVIGATE ESUS Investigators : Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source : a prespecified subgroup analysis from the NAVIGATE ESUS trial. Lancet Neurol 2018 ; 17 : 1053-1060
 
11) Lee PH, Song JK, Kim JS, et al : Cryptogenic Stroke and High-Risk Patent Foramen Ovale The DEFENSE-PFO Trial. J Am Coll Cardiol 2018 ; 71 : 2335-2342
 
12) Agnelli G, Buller HR, Cohen A, et al ; AMPLIFY Investigators : Oral Apixaban for the Treatment of Acute Venous Thromboembolism. N Engl J Med 2013 ; 369 : 799-808
 
13) EINSTEIN Investigators ; Bauersachs R, Berkowitz SD, Brenner B, et al : Oral Rivaroxaban for Symptomatic Venous Thromboembolism. N Engl J Med 2010 ; 363 : 2499-2510
 
P.775 掲載の参考文献
1) Barrios D, Rosa-Salazar V, Jimenez D, et al ; RIETE investigators : Right heart thrombi in pulmonary embolism. Eur Respir J 2016 ; 48 : 1377-1385
 
2) Casazza F, Bongarzoni A, Centonze F, Morpurgo M : Prevalence and prognostic significance of right-sided cardiac mobile thrombi in acute massive pulmonary embolism. Am J Cardiol 1997 ; 79 : 1433-1435
 
3) Perrier A, Roy PM, Aujesky D, et al : Diagnosing pulmonary embolism in outpatients with clinical assessment, D-dimer measurement, venous ultrasound, and helical computed tomography : a multicenter management study. Am J Med 2004 ; 116 : 291-299
 
4) 日本循環器学会 : 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/09/JCS2017_ito.pdf
 
5) Rivera-Lebron B, McDaniel M, Ahrar K, et al ; PERT Consortium : Diagnosis, Treatment and Follow Up of Acute Pulmonary Embolism : Consensus Practice from the PERT Consortium. Clin Appl Thromb Hemost 2019 ; 25 : 1076029619853037
PubMed
P.778 掲載の参考文献
1) Kuroiwa M, Morimatsu H, Tsuzaki K, et al : Changes in the incidence, case fatality rate, and characteristics of symptomatic perioperative pulmonary thromboembolism in Japan : Results of the 2002-2011 Japanese Society of Anesthesiologists Perioperative Pulmonary Thromboembolism (JSA-PTE) Study. J Anesth 2015 ; 29 : 433-441
 
2) Nakamura M, Fujioka H, Yamada N, et al : Clinical characteristics of acute pulmonary thromboembolism in Japan : results of a multicenter registry in the Japanese Society of Pulmonary Embolism Research. Clin Cardiol 2001 ; 24 : 132-138
 
3) 日本循環器学会 : 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/09/JCS2017_ito.pdf
 
4) Key NS, Khorana AA, Kuderer NM, et al : Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer : ASCO Clinical Practice Guideline Update. J Clin Oncol 2020 ; 38 : 496-520
 
5) Khorana AA, Kuderer NM, Culakova E, et al : Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008 ; 111 : 4902-4907
 
6) Farge D, Frere C, Connors JM, et al ; International Initiative on Thrombosis and Cancer (ITAC) advisory panel : 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 2022 ; 23 : e334-e347
 
7) Streiff MB, Holmstrom B, Angelini D, et al : Cancer-Associated Venous Thromboembolic Disease, Version 2. 2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021 ; 19 : 1181-1201
 
8) Insin P, Vitoopinyoparb K, Thadanipon K, et al : Prevention of venous thromboembolism in gynecological cancer patients undergoing major abdominopelvic surgery : a systematic review and network meta-analysis. Gynecol Oncol 2021 ; 161 : 304-313
 
9) Bisch S, Findley R, Ince C, et al : Efficacy of pre-operative pharmacologic thromboprophylaxis on incidence of venous thromboembolism following major gynecologic and gynecologic oncology surgery : a systematic review and meta-analysis. Int J Gynecol Cancer 2021 ; 31 : 257-264
 
10) Guntupalli SR, Brennecke A, Behbakht K, et al : Safety and efficacy of apixaban vs enoxaparin for preventing postoperative venous thromboembolism in women undergoing surgery for gynecologic malignant neoplasm : a randomized clinical trial. JAMA Netw Open 2020 ; 3 : e207410
PubMed

書評

最近チェックした商品履歴

Loading...